SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15

M. Tessema, C. M. Yingling, C. L. Thomas, D. M. Klinge, A. M. Bernauer, Y. Liu, S. Dacic, J. M. Siegfried, S. E. Dahlberg, J. H. Schiller, S. A. Belinsky

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

The heparan sulfate 6-O-endosulfatase (SULF2) promotes growth and metastasis of solid tumors. We recently identified that cytosine methylation of the SULF2 promoter is associated with better survival of resected lung adenocarcinoma patients, and now also demonstrates a marginal improvement in survival of advanced non-small cell lung cancer (NSCLC) patients receiving standard chemotherapy (hazard ratio0.63, P0.07). Subsequent studies focused on investigating the effect of methylation on SULF2 expression and its genome-wide impact. The genes and pathways modulated by epigenetic inactivation of SULF2 and the effects on sensitivity to chemotherapy were characterized in vitro and in vivo. Silencing SULF2 through small interfering RNA or methylation primarily increased expression of interferon-inducible genes including ISG15, a marker for increased sensitivity to topoisomerase-1 inhibitors such as camptothecin (CPT). NSCLC cell lines with methylated SULF2 (SULF2M) express 60-fold higher ISG15 compared with SULF2 unmethylated (SULF2U) NSCLC cell lines and normal human bronchial epithelial cells. In vitro, SULF2M and high ISG15 (ISG15H)-expressing NSCLC cell lines were 134-fold more sensitive to CPT than SULF2U and low ISG15 (ISG15L)-expressing cell lines. Topotecan, a soluble analog of CPT and FDA-approved anticancer drug, dramatically arrested the growth of SULF2M-ISG15H, but not SULF2U-ISG15L lung tumors in nude mice (P0.002). Similarly, high ISG15 expression that is comparable to the topotecan (TPT)-sensitive NSCLC cell lines was found in tumors from 25% of NSCLC patients compared with normal lung, indicating a potential to identify and target the most sensitive NSCLC subpopulation for personalized TPT therapy.

Original languageEnglish (US)
Pages (from-to)4107-4116
Number of pages10
JournalOncogene
Volume31
Issue number37
DOIs
StatePublished - Sep 2012

Fingerprint

Topoisomerase I Inhibitors
Non-Small Cell Lung Carcinoma
Methylation
Lung Neoplasms
Survival
Topotecan
Camptothecin
Cell Line
Drug Therapy
Neoplasms
Lung
Heparitin Sulfate
Cytosine
Growth
Epigenomics
Nude Mice
Interferons
Small Interfering RNA
Genes
Epithelial Cells

Keywords

  • camptothecin
  • NSCLC
  • SULF-2
  • topotecan

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Tessema, M., Yingling, C. M., Thomas, C. L., Klinge, D. M., Bernauer, A. M., Liu, Y., ... Belinsky, S. A. (2012). SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15. Oncogene, 31(37), 4107-4116. https://doi.org/10.1038/onc.2011.577

SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15. / Tessema, M.; Yingling, C. M.; Thomas, C. L.; Klinge, D. M.; Bernauer, A. M.; Liu, Y.; Dacic, S.; Siegfried, J. M.; Dahlberg, S. E.; Schiller, J. H.; Belinsky, S. A.

In: Oncogene, Vol. 31, No. 37, 09.2012, p. 4107-4116.

Research output: Contribution to journalArticle

Tessema, M, Yingling, CM, Thomas, CL, Klinge, DM, Bernauer, AM, Liu, Y, Dacic, S, Siegfried, JM, Dahlberg, SE, Schiller, JH & Belinsky, SA 2012, 'SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15', Oncogene, vol. 31, no. 37, pp. 4107-4116. https://doi.org/10.1038/onc.2011.577
Tessema, M. ; Yingling, C. M. ; Thomas, C. L. ; Klinge, D. M. ; Bernauer, A. M. ; Liu, Y. ; Dacic, S. ; Siegfried, J. M. ; Dahlberg, S. E. ; Schiller, J. H. ; Belinsky, S. A. / SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15. In: Oncogene. 2012 ; Vol. 31, No. 37. pp. 4107-4116.
@article{348f360f22a84f2ca4b981eee5cb4d0d,
title = "SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15",
abstract = "The heparan sulfate 6-O-endosulfatase (SULF2) promotes growth and metastasis of solid tumors. We recently identified that cytosine methylation of the SULF2 promoter is associated with better survival of resected lung adenocarcinoma patients, and now also demonstrates a marginal improvement in survival of advanced non-small cell lung cancer (NSCLC) patients receiving standard chemotherapy (hazard ratio0.63, P0.07). Subsequent studies focused on investigating the effect of methylation on SULF2 expression and its genome-wide impact. The genes and pathways modulated by epigenetic inactivation of SULF2 and the effects on sensitivity to chemotherapy were characterized in vitro and in vivo. Silencing SULF2 through small interfering RNA or methylation primarily increased expression of interferon-inducible genes including ISG15, a marker for increased sensitivity to topoisomerase-1 inhibitors such as camptothecin (CPT). NSCLC cell lines with methylated SULF2 (SULF2M) express 60-fold higher ISG15 compared with SULF2 unmethylated (SULF2U) NSCLC cell lines and normal human bronchial epithelial cells. In vitro, SULF2M and high ISG15 (ISG15H)-expressing NSCLC cell lines were 134-fold more sensitive to CPT than SULF2U and low ISG15 (ISG15L)-expressing cell lines. Topotecan, a soluble analog of CPT and FDA-approved anticancer drug, dramatically arrested the growth of SULF2M-ISG15H, but not SULF2U-ISG15L lung tumors in nude mice (P0.002). Similarly, high ISG15 expression that is comparable to the topotecan (TPT)-sensitive NSCLC cell lines was found in tumors from 25{\%} of NSCLC patients compared with normal lung, indicating a potential to identify and target the most sensitive NSCLC subpopulation for personalized TPT therapy.",
keywords = "camptothecin, NSCLC, SULF-2, topotecan",
author = "M. Tessema and Yingling, {C. M.} and Thomas, {C. L.} and Klinge, {D. M.} and Bernauer, {A. M.} and Y. Liu and S. Dacic and Siegfried, {J. M.} and Dahlberg, {S. E.} and Schiller, {J. H.} and Belinsky, {S. A.}",
year = "2012",
month = "9",
doi = "10.1038/onc.2011.577",
language = "English (US)",
volume = "31",
pages = "4107--4116",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "37",

}

TY - JOUR

T1 - SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15

AU - Tessema, M.

AU - Yingling, C. M.

AU - Thomas, C. L.

AU - Klinge, D. M.

AU - Bernauer, A. M.

AU - Liu, Y.

AU - Dacic, S.

AU - Siegfried, J. M.

AU - Dahlberg, S. E.

AU - Schiller, J. H.

AU - Belinsky, S. A.

PY - 2012/9

Y1 - 2012/9

N2 - The heparan sulfate 6-O-endosulfatase (SULF2) promotes growth and metastasis of solid tumors. We recently identified that cytosine methylation of the SULF2 promoter is associated with better survival of resected lung adenocarcinoma patients, and now also demonstrates a marginal improvement in survival of advanced non-small cell lung cancer (NSCLC) patients receiving standard chemotherapy (hazard ratio0.63, P0.07). Subsequent studies focused on investigating the effect of methylation on SULF2 expression and its genome-wide impact. The genes and pathways modulated by epigenetic inactivation of SULF2 and the effects on sensitivity to chemotherapy were characterized in vitro and in vivo. Silencing SULF2 through small interfering RNA or methylation primarily increased expression of interferon-inducible genes including ISG15, a marker for increased sensitivity to topoisomerase-1 inhibitors such as camptothecin (CPT). NSCLC cell lines with methylated SULF2 (SULF2M) express 60-fold higher ISG15 compared with SULF2 unmethylated (SULF2U) NSCLC cell lines and normal human bronchial epithelial cells. In vitro, SULF2M and high ISG15 (ISG15H)-expressing NSCLC cell lines were 134-fold more sensitive to CPT than SULF2U and low ISG15 (ISG15L)-expressing cell lines. Topotecan, a soluble analog of CPT and FDA-approved anticancer drug, dramatically arrested the growth of SULF2M-ISG15H, but not SULF2U-ISG15L lung tumors in nude mice (P0.002). Similarly, high ISG15 expression that is comparable to the topotecan (TPT)-sensitive NSCLC cell lines was found in tumors from 25% of NSCLC patients compared with normal lung, indicating a potential to identify and target the most sensitive NSCLC subpopulation for personalized TPT therapy.

AB - The heparan sulfate 6-O-endosulfatase (SULF2) promotes growth and metastasis of solid tumors. We recently identified that cytosine methylation of the SULF2 promoter is associated with better survival of resected lung adenocarcinoma patients, and now also demonstrates a marginal improvement in survival of advanced non-small cell lung cancer (NSCLC) patients receiving standard chemotherapy (hazard ratio0.63, P0.07). Subsequent studies focused on investigating the effect of methylation on SULF2 expression and its genome-wide impact. The genes and pathways modulated by epigenetic inactivation of SULF2 and the effects on sensitivity to chemotherapy were characterized in vitro and in vivo. Silencing SULF2 through small interfering RNA or methylation primarily increased expression of interferon-inducible genes including ISG15, a marker for increased sensitivity to topoisomerase-1 inhibitors such as camptothecin (CPT). NSCLC cell lines with methylated SULF2 (SULF2M) express 60-fold higher ISG15 compared with SULF2 unmethylated (SULF2U) NSCLC cell lines and normal human bronchial epithelial cells. In vitro, SULF2M and high ISG15 (ISG15H)-expressing NSCLC cell lines were 134-fold more sensitive to CPT than SULF2U and low ISG15 (ISG15L)-expressing cell lines. Topotecan, a soluble analog of CPT and FDA-approved anticancer drug, dramatically arrested the growth of SULF2M-ISG15H, but not SULF2U-ISG15L lung tumors in nude mice (P0.002). Similarly, high ISG15 expression that is comparable to the topotecan (TPT)-sensitive NSCLC cell lines was found in tumors from 25% of NSCLC patients compared with normal lung, indicating a potential to identify and target the most sensitive NSCLC subpopulation for personalized TPT therapy.

KW - camptothecin

KW - NSCLC

KW - SULF-2

KW - topotecan

UR - http://www.scopus.com/inward/record.url?scp=84859324880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859324880&partnerID=8YFLogxK

U2 - 10.1038/onc.2011.577

DO - 10.1038/onc.2011.577

M3 - Article

VL - 31

SP - 4107

EP - 4116

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 37

ER -